Researchers have discovered a natural plant compound that might provide an unexpected new method for addressing rheumatoid arthritis. In experiments involving rats, this substance showed promise by reducing joint swelling, safeguarding cartilage, and easing harmful immune responses. Interestingly, the compound operates through a surprising mechanism related to the body’s fat processing.
The study, published in the journal Engineering, focuses on a compound named obakulactone (OL), a naturally occurring tetracyclic triterpenoid derived from the bark of the Phellodendri cortex plant. Tetracyclic triterpenoids are plant-derived compounds characterized by a unique structure with four interconnected rings.
Researchers discovered that obakulactone aids in rebalancing unsaturated fatty acids, which are crucial for cellular functions and inflammation control. It achieves this by facilitating the breakdown of a protein known as acyl coenzyme A thioesterase 1 (ACOT1) through the cell’s inherent protein disposal mechanism, recognized as the ubiquitin‒proteasome pathway.
This exploration of a previously overlooked molecular target suggests that altering how cells handle fatty acids might become a novel approach for treating rheumatoid arthritis (RA).
Natural Compound Reduces Arthritis Inflammation and Joint Damage
To assess the effects of obakulactone, scientists developed a rat model of rheumatoid arthritis using complete Freund’s adjuvant (CFA), a substance that provokes a robust inflammatory response similar to aspects of the disease.
The rats were administered obakulactone over 21 days at three different doses based on their body weight: low (50 mg·kg⁻¹·d⁻¹), medium (100 mg·kg⁻¹·d⁻¹), and high (200 mg·kg⁻¹·d⁻¹).
The results were quite promising. The rats treated with the compound showed a significant reduction in joint swelling, while their cartilage and synovium— the membrane lining the joints—returned closer to normal. In cases of rheumatoid arthritis, the synovium can become inflamed and hinder joint function.
The treatment also produced beneficial changes in the thymus and spleen, organs integral to the immune system.
Beyond physical enhancements, researchers noted substantial alterations in immune activity as well. Obakulactone lowered elevated levels of CD3⁺ T cells and CD68⁺ macrophages within joint tissues. While these immune cells typically defend the body, they can lead to ongoing inflammation and tissue damage when overactive.
Furthermore, the compound encouraged a shift in macrophages from an inflammation-promoting M1 state toward a resolution-focused M2 state. It also suppressed the transformation of CD4⁺ T cells into Th17 cells, which are associated with autoimmune inflammation.
Blood tests further confirmed these effects, indicating that obakulactone decreased various inflammatory signaling proteins, including IL-1β, IL-6, IL-17, and TNF-α. These cytokines facilitate communication among immune cells, but excessive production can exacerbate inflammation.
The treatment also diminished rheumatoid arthritis-related blood markers such as rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (CCP-Ab), C-reactive protein (CRP), and matrix metalloproteinase-3 (MMP-3), with more significant reductions observed with increased dosing.
Scientists Uncover a Surprising Link Between Fat Metabolism and Arthritis
One of the more fascinating findings of the study involved fatty acids, commonly linked with nutrition and energy, but also influential in inflammation throughout the body.
By employing advanced analytical methods like metabolomics, MALDI mass spectrometry imaging, and proteomics, the researchers analyzed how obakulactone influenced chemical processes within tissues.
These techniques enabled them to explore changes in small molecules, visualize their distribution within tissues, and assess variations in protein levels.
The analysis revealed that this compound improved imbalances in the production and breakdown of unsaturated fatty acids, including arachidonic acid, linoleic acid, and α-linolenic acid.
These fatty acids are vital for cell membranes and can be precursors to molecules that regulate inflammation. Arachidonic acid, notably, plays a key role in generating potent inflammatory signals.
For the arthritic rats, obakulactone helped to restore these disrupted metabolic processes, indicating that its advantages may go beyond merely suppressing immune activity.
A Hidden Protein Emerges as a Potential Treatment Target
To gain further insight into how the compound operates, scientists conducted additional laboratory studies with rheumatoid arthritis synovial fibroblasts (SFs).
SFs contribute to maintaining the joint lining tissue, but in rheumatoid arthritis, they can become overly aggressive, rapidly multiplying, releasing inflammatory substances, and leading to cartilage destruction and tissue scarring.
Obakulactone was found to slow the growth of these cells, reduce their production of inflammatory cytokines, and promote apoptosis, the body’s way of eliminating damaged or unwanted cells.
To pinpoint the specific protein targeted by the compound, researchers used techniques like cellular thermal shift assays, microscale thermophoresis, and surface plasmon resonance to identify ACOT1 as the direct molecular target of obakulactone.
They obtained binding measurements indicating the strength of the compound’s interaction with ACOT1, providing evidence of a significant connection. The dissociation constant values indicated a strong binding affinity.
Notably, obakulactone not only bound to the protein but also facilitated its degradation through the ubiquitin‒proteasome system, which dismantles proteins for removal. This degradation resulted in reduced activity of various downstream mechanisms linked to inflammation and abnormal cell behavior.
How Targeting One Protein Can Disrupt Inflammation
Once ACOT1 was broken down, the levels of an enzyme known as stearoyl-CoA desaturase-1 (SCD1) also diminished. This enzyme is crucial for producing certain unsaturated fatty acids.
These changes subsequently suppressed two major cellular signaling networks: Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT).
These pathways act as internal communication systems, transmitting signals that affect cell growth, survival, and responsiveness to the environment. When these pathways malfunction, they can contribute to inflammation and excessive tissue growth.
By disrupting these signaling interactions, obakulactone lessened inflammation and fibrosis—excessive connective tissue buildup— in the rheumatoid arthritis synovial fibroblasts.
Follow-up experiments supported the critical role of ACOT1 in these effects, affirming that the compound’s efficacy in reducing inflammation, curbing abnormal cell growth, and promoting apoptosis depended on its influence over ACOT1 and the associated signaling pathways.
The overall findings suggest a potential method of interrupting the biological processes responsible for sustaining arthritis-related inflammation, rather than merely focusing on immune response suppression.
A Potential New Direction for Rheumatoid Arthritis Treatment
Rheumatoid arthritis is a persistent autoimmune condition where the immune system mistakenly attacks the body’s tissues, particularly the joints, impacting about 1% of the global population. It can lead to continual pain, swelling, stiffness, and ongoing joint deterioration.
Since it’s a systemic illness, rheumatoid arthritis can also affect various organs and tissues beyond the joints.
Although current treatments can alleviate symptoms and slow disease advancement, their effectiveness varies, and some treatments carry severe side effects, highlighting the need for alternative therapies.
The recent discoveries suggest that obakulactone could be a valuable candidate for future rheumatoid arthritis drug development, pinpointing ACOT1 as an important treatment target and underscoring the significance of unsaturated fatty acid metabolism in managing inflammation.
Nonetheless, these results are still in the preclinical stage. While the compound has shown efficacy in rats and lab cells, further research is essential to evaluate its safety and effectiveness in humans.
Despite this limitation, the findings present an interesting possibility: targeting the metabolic mechanisms that drive inflammation could offer a new way to tackle rheumatoid arthritis and potentially safeguard joints from enduring damage.
